Shah Capital Management Has Lowered Vitamin Shoppe (VSI) Holding by $911,420; First Midwest Bank Trust Division Boosted Its Intra Cellular Therapies (ITCI) Stake by $543,480

Vitamin Shoppe, Inc. (NYSE:VSI) Logo

First Midwest Bank Trust Division increased its stake in Intra Cellular Therapies Inc (ITCI) by 14.49% based on its latest 2018Q3 regulatory filing with the SEC. First Midwest Bank Trust Division bought 25,880 shares as the company’s stock declined 28.78% with the market. The institutional investor held 204,470 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $4.44 million, up from 178,590 at the end of the previous reported quarter. First Midwest Bank Trust Division who had been investing in Intra Cellular Therapies Inc for a number of months, seems to be bullish on the $726.77 million market cap company. The stock increased 1.07% or $0.14 during the last trading session, reaching $13.28. About 121,116 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has risen 1.66% since January 11, 2018 and is uptrending. It has outperformed by 1.66% the S&P500. Some Historical ITCI News: 31/05/2018 – Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual…; 31/05/2018 – Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual; 11/05/2018 – Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of the Dopaminergic and Glutamatergic Systems, and a Serotonin Reuptake Inhibitor – ResearchAndMarkets; 29/05/2018 – Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; 09/05/2018 – Intra-Cellular Presenting at Bank of America Conference May 16; 13/03/2018 – INTRA-CELLULAR THERAPIES INC – FDA AGREED ON PROPOSED CONTENT AND TIMING OF A ROLLING NDA SUBMISSION; 15/05/2018 – Pointstate Capital Buys New 3.4% Position in Intra-Cellular; 03/05/2018 – Intra-Cellular Therapies 1Q Loss $35.5M; 29/05/2018 – Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP); 04/05/2018 – Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences

Shah Capital Management decreased its stake in Vitamin Shoppe Inc (VSI) by 2.13% based on its latest 2018Q3 regulatory filing with the SEC. Shah Capital Management sold 91,142 shares as the company’s stock declined 54.98% with the market. The hedge fund held 4.18 million shares of the consumer non-durables company at the end of 2018Q3, valued at $41.82M, down from 4.27 million at the end of the previous reported quarter. Shah Capital Management who had been investing in Vitamin Shoppe Inc for a number of months, seems to be less bullish one the $123.85M market cap company. The stock increased 2.93% or $0.15 during the last trading session, reaching $5.27. About 211,641 shares traded. Vitamin Shoppe, Inc. (NYSE:VSI) has risen 64.44% since January 11, 2018 and is uptrending. It has outperformed by 64.44% the S&P500. Some Historical VSI News: 09/05/2018 – Vitamin Shoppe Sees 2018 Capital Expenditures About $30M; 19/03/2018 – Vintage Capital Management Reports 14.8% Stake in Vitamin Shoppe; 01/05/2018 – Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Br; 18/05/2018 – Vitamin Shoppe Announces Chief Financial Officer Resignation; 09/05/2018 – VITAMIN SHOPPE INC – SEES FY 2018 COMP SALES OF NEGATIVE LOW TO MID SINGLE DIGITS; 21/04/2018 – DJ Vitamin Shoppe Inc, Inst Holders, 1Q 2018 (VSI); 19/03/2018 – Vitamin Shoppe Shareholders Vintage Capital Management and Shah Capital Management Seek Board Representation – Filing; 18/05/2018 – Vitamin Shoppe Promotes Bill Wafford as New Chief Financial Officer; 09/05/2018 – VITAMIN SHOPPE INC – SOLD NUTRI-FORCE, ITS MANUFACTURING BUSINESS FOR NET PROCEEDS OF ABOUT $15 MLN TO ARIZONA NUTRITIONAL SUPPLEMENTS; 23/04/2018 – VITAMIN SHOPPE INC – ALSO ENTERED INTO COOPERATION AGREEMENTS WITH SHAH CAPITAL MANAGEMENT AND CERTAIN OF ITS AFFILIATES

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Fool.com which released: “Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc. – Motley Fool” on July 25, 2018, also Streetinsider.com with their article: “Intra-Cellular Therapies (ITCI) Announces FDA Acceptance of NDA for Lumateperone for Treatment of Schizophrenia – StreetInsider.com” published on December 11, 2018, Globenewswire.com published: “Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease – GlobeNewswire” on October 23, 2018. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: Globenewswire.com and their article: “Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting – GlobeNewswire” published on October 17, 2018 as well as Nasdaq.com‘s news article titled: “Week Ahead In Pharmaceuticals: 11 Stocks To Watch (MRTX, EPZM, ITCI…) – Nasdaq” with publication date: October 22, 2018.

Among 13 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Intra-Cellular Therapies had 50 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Thursday, March 1 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, September 25. On Wednesday, November 8 the stock rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, June 6 the stock rating was maintained by Cowen & Co with “Buy”. The firm earned “Outperform” rating on Friday, November 6 by RBC Capital Markets. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 9 report. The stock has “Buy” rating by SunTrust on Friday, March 2. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, September 7. The stock has “Buy” rating by Cowen & Co on Wednesday, August 9. On Thursday, March 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

Since November 9, 2018, it had 0 insider purchases, and 7 insider sales for $1.99 million activity. Another trade for 9,564 shares valued at $109,630 was sold by Davis Robert E. The insider Halstead Michael sold $284,418. MARCUS JOEL S had sold 32,000 shares worth $581,580 on Friday, November 9. $284,383 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares were sold by Hineline Lawrence J.. $116,979 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was sold by Vanover Kimberly E..

First Midwest Bank Trust Division, which manages about $743.62 million US Long portfolio, decreased its stake in Ishares Tr (IVW) by 36,106 shares to 61,002 shares, valued at $10.81 million in 2018Q3, according to the filing. It also reduced its holding in Kimberly Clark Corp (NYSE:KMB) by 3,130 shares in the quarter, leaving it with 27,797 shares, and cut its stake in Lilly Eli & Co (NYSE:LLY).

Investors sentiment decreased to 0.94 in Q3 2018. Its down 0.30, from 1.24 in 2018Q2. It fall, as 9 investors sold ITCI shares while 39 reduced holdings. 11 funds opened positions while 34 raised stakes. 36.60 million shares or 0.99% less from 36.97 million shares in 2018Q2 were reported. Da Davidson And Commerce has 9,298 shares. Hbk Invs LP reported 0% stake. Vanguard Incorporated owns 3.94 million shares. Gemmer Asset Management Ltd Limited Liability Company reported 10,000 shares. Wasatch Advsr Incorporated holds 0.48% or 1.93 million shares in its portfolio. Dubuque National Bank & Trust & Tru Com has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Tocqueville Asset Management LP invested in 0.01% or 25,060 shares. Panagora Asset Inc holds 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 44,645 shares. 501,624 are owned by Clough Cap Ptnrs Lp. Moreover, Royal Bancorp Of Canada has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Moreover, Hanseatic Mgmt Service Inc has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 42 shares. Columbus Circle reported 493,608 shares or 0.21% of all its holdings. Art Limited Liability invested 0.04% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Wells Fargo And Mn holds 25,719 shares or 0% of its portfolio. Blume Capital Management owns 1,000 shares for 0.01% of their portfolio.

More notable recent Vitamin Shoppe, Inc. (NYSE:VSI) news were published by: Benzinga.com which released: “GNC Holdings, Inc. (NYSE:GNC), Vitamin Shoppe, Inc (NYSE:VSI) – Natural And Specialty Retail Hemp-Derived CBD Sales Projected To Grow By More Than 600% By 2022 – Benzinga” on August 29, 2018, also Benzinga.com with their article: “55 Biggest Movers From Yesterday – Benzinga” published on November 14, 2018, Benzinga.com published: “6 Reasons Vitamin Shoppe (NYSE: VSI) Likely To Remain Under Pressure – Benzinga” on May 12, 2017. More interesting news about Vitamin Shoppe, Inc. (NYSE:VSI) were released by: Seekingalpha.com and their article: “Vitamin Shoppe: Getting Crushed From All Sides – Seeking Alpha” published on August 22, 2017 as well as Seekingalpha.com‘s news article titled: “The Insiders Are Buying: Are You? – Seeking Alpha” with publication date: June 21, 2018.

Analysts await Vitamin Shoppe, Inc. (NYSE:VSI) to report earnings on February, 26. They expect $-0.29 earnings per share, down 70.59% or $0.12 from last year’s $-0.17 per share. After $0.04 actual earnings per share reported by Vitamin Shoppe, Inc. for the previous quarter, Wall Street now forecasts -825.00% negative EPS growth.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.